# ‚öîÔ∏è **UC BERKELEY CONQUEST: DEMONSTRATION SCRIPT** ‚öîÔ∏è

**PRESENTER:** FAHAD KIANI, GENERAL COMMANDER, ZETA DIVISION
**PLATFORM:** CRISPRO - AGENTIC THERAPEUTICS PLATFORM

---

### **OPENING STATEMENT**

**(The screen shows the main landing page of the Streamlit application)**

**PRESENTER:** "Good morning. For the last 30 years, bioinformatics has given us better maps of the battlefield. But maps don't win wars. Today, we're not here to show you another map. We are here to demonstrate a command and control system.

We've built an agentic platform that executes a full, end-to-end kill chain‚Äîfrom identifying a threat, to modeling its spread, to forging the weapon that will kill it. Let me show you."

---

### **ACT I: THE THREAT (Intelligence)**

*   **ACTION:** Navigate to the **`Threat Assessor`** page (`2_‚öîÔ∏è_Threat_Assessor.py`).

*   **NARRATIVE:** "Our story begins with a patient with RUNX1-FPD, a hereditary disorder that predisposes them to leukemia. The question is not *if* they will get cancer, but *when*, and what will be the trigger. This is the 'Two-Hit' model. Our platform's first job is to identify that dangerous second hit.

*   **ACTION:** In the 'Second Hit' panel, confirm the target is `ASXL1` with protein change `p.G646fs*12`. Click **"‚ö° Assess Second Hit Threat"**.

*   **PAYOFF:** "The system makes a live call to our intelligence engine, The Oracle. Instantly, we have a verdict. The Truncation Sieve identifies this as a catastrophic, protein-destroying mutation. The `is_pathogenic` flag is TRUE. We have found the enemy. But a single soldier is not an army. We must now understand the enemy's capacity to spread."

---

### **ACT II: THE SPREAD (Systemic Modeling)**

*   **ACTION:** Navigate to the **`Seed & Soil Analysis`** page (`4_üå±_Seed_and_Soil_Analysis.py`). The page should show the `ASXL1` threat has been handed off.

*   **NARRATIVE:** "This brings us to Act II: The Spread. This is the 'Seed & Soil' problem. Our platform seamlessly takes the validated ASXL1 'seed' and deploys our **Metastasis Forecaster**. First, we task the system to find the most likely 'soil' for this seed."

*   **ACTION:** Click **"üîç Query Threat Matrix"** and **"ü§ñ Analyze Literature"**.

*   **NARRATIVE:** "The system fuses intelligence from genomic databases and biomedical literature, identifying the Spleen as a high-risk microenvironment. Now, we run the `in silico` experiment."

*   **ACTION:** Click **"üî¨ Generate Baseline Tissue Profile"** and then **"‚ö° Simulate Seed Invasion"**.

*   **PAYOFF:** "Our platform creates a digital twin of the spleen's microenvironment and 'stresses' it with the ASXL1 mutation. The result is a **Seed-Soil Compatibility Score**‚Äîa single, quantifiable metric of metastatic risk. The risk is high. We now have an actionable secondary target: the spleen itself. The mission becomes clear: we must poison the soil."

---

### **ACT III: THE WEAPON (Therapeutic Design)**

*   **ACTION:** Navigate to the **`CHOPCHOP Guide Designer`** page (`5_‚úÇÔ∏è_CHOPCHOP_Guide_Design.py`). The page should show the target gene has been handed off.

*   **NARRATIVE:** "The intelligence is clear. This brings us to Act III: The Weapon. Our platform hands off the 'soil poisoning' target gene to **The Armory** to forge the weapon."

*   **ACTION:** Click **"Design & Validate Guides"**.

*   **NARRATIVE:** "The system instantly forges a set of candidate gRNA weapons. This isn't just a list; it's a dossier. Let's select the top candidate and run a live, on-demand safety validation."

*   **ACTION:** Click the **"Validate Safety"** button next to the top-ranked guide.

*   **PAYOFF:** "The off-target analysis is clean. In less than three minutes, we have gone from a patient's raw mutation data, to a systemic metastatic risk assessment, to a validated, high-precision weapon ready for synthesis."

---

### **ACT IV: THE KILL CHAIN (The Grand Finale)**

*   **ACTION:** Navigate to the **`Myeloma Digital Twin`** page (`6_Myeloma_Digital_Twin.py`).

*   **NARRATIVE:** "This entire workflow‚Äîfrom threat to weapon‚Äîis our core competency. Now, let me show you how it all comes together at the point of care in a different, more complex disease. This is our **Myeloma Digital Twin**. We have a patient with multiple myeloma, evolving under therapeutic pressure. Let's input their latest biopsy results."

*   **ACTION:** Enter the `KRAS` and `TP53` mutations. Click **"üöÄ Analyze Drug Response"**.

*   **PAYOFF 1:** "Our platform analyzes these mutations *at the pathway level*. The verdict is clear: high impact on the RAS/MAPK pathway. The prediction: **Likely Resistant**. This tells the clinician, with a high degree of confidence, that their current therapy is futile."

*   **THE MIC DROP:** "But we do not just deliver bad news. We provide the solution. For this primary KRAS driver mutation, our platform presents a single, powerful command."

*   **ACTION:** Click the **"üéØ Design CRISPR Therapy"** button that appears next to the high-impact KRAS variant.

*   **FINAL PAYOFF:** (The screen seamlessly navigates to the Guide Designer). "And the kill chain begins again. We have gone from patient data to a new therapeutic path in seconds. This is the future of medicine. Thank you."

---

### **CONTINGENCY SCRIPTS (For Audience Q&A)**

*   **IF ASKED ABOUT CLINICAL EVIDENCE:**
    *   **PIVOT:** Navigate to **`RadOnc Co-Pilot`**.
    *   **SCRIPT:** "An excellent question. Our models are not built in a vacuum. They are validated against real-world clinical data. For example, here's an analysis we ran on the TCGA dataset, showing a powerful correlation between TP53 mutation status and radiotherapy response. We use these kinds of real-world findings to continuously validate and refine our predictive engines."

*   **IF ASKED ABOUT BUSINESS / COMMERCIAL APPLICATION:**
    *   **PIVOT:** Navigate to **`Trial Conquest`**.
    *   **SCRIPT:** "That's a critical point. Our platform's value extends beyond therapeutic design. We've weaponized our deep biological understanding to solve one of the biggest logistical and economic problems in pharma: clinical trial recruitment. We create 'Digital Twins' of both patients and trials to match them on biological intent, not just keywords. We call it 'Biological Warfare Matching,' and it's designed to end the multi-billion dollar failure of trial logistics."

*   **IF ASKED ABOUT OTHER THERAPEUTIC TYPES (Non-CRISPR):**
    *   **PIVOT:** Navigate to **`Interception Design Studio`**.
    *   **SCRIPT:** "Absolutely. While we believe gene editing is the ultimate solution, our platform is modality-agnostic. For any validated target, our **Interception Design Studio** can attack it from multiple angles. We can generate novel biologics like nanobodies *de novo*, or run massive virtual screens to find existing, repurposable drugs that can be brought to the clinic faster and cheaper. We design the best weapon for the specific war." 